Deal Library / Pharma BD Deal Intelligence

Novartis AG — Pharma Deals

The Pharma Closeout tracks 58 deals, $223.5B in disclosed deal value, 40 with a post-close Outcome Score for Novartis AG.

Median Critic Score: 75  ·  Median Outcome Score: 56

Best outcome: Novartis AG / Advanced Accelerator Applications S.A. (98)  ·  Weakest outcome: Novartis AG / Ziarco Group Limited (12)

All 58 deals

• Novartis AG / Advanced Accelerator Applications S.A. — 2017 · $3.9B · Worked — the deal delivered on its rationale.
• Novartis AG / Endocyte, Inc. — 2018 · $2.1B · Worked — the deal delivered on its rationale.
• Novartis AG / Lek Pharmaceuticals d.d. — 2002 · $876M · Worked — the deal delivered on its rationale.
• Novartis AG / GlaxoSmithKline plc — 2014 · $16.0B · Worked — the deal delivered on its rationale.
• Novartis AG / PTC Therapeutics Inc. — 2024 · $2.9B · Worked — the deal delivered on its rationale.
• Novartis AG / Chinook Therapeutics Inc. — 2023 · $3.5B · Worked — the deal delivered on its rationale.
• Novartis AG / Hexal AG — 2002 · $8.3B · Worked — the deal delivered on its rationale.
• Novartis AG / Anthos Therapeutics — 2025 · $3.1B · Largely worked — most objectives met.
• Novartis AG / PeptiDream Inc. — 2024 · $2.9B · Largely worked — most objectives met.
• Novartis AG / Shanghai Argo Biopharmaceutical Co. Ltd. — 2024 · $4.2B · Largely worked — most objectives met.
• Novartis AG / Legend Biotech Corporation — 2023 · $1.1B · Largely worked — most objectives met.
• Novartis AG / AveXis Inc. — 2018 · $8.7B · Largely worked — most objectives met.
• Novartis AG / The Medicines Company — 2002 · $9.7B · Largely worked — most objectives met.
• Novartis AG / Mead Johnson Adult Medical Nutrition (BMS divestiture) — 2003 · $385M · Largely worked — most objectives met.
• Novartis AG / Myricx Bio Ltd. — 2026 · $1.5B · Largely worked — most objectives met.
• Novartis AG / Regulus Therapeutics — 2025 · $1.7B · Largely worked — most objectives met.
• Novartis AG / Voyager Therapeutics Inc. — 2024 · $1.3B · Largely worked — most objectives met.
• Novartis AG / Chai Discovery, Inc. — 2026 · Mixed — partial payoff, real shortfalls.
• Novartis AG / Orionis Biosciences, Inc. — 2026 · $1.4B · Mixed — partial payoff, real shortfalls.
• Novartis AG / Monte Rosa Therapeutics Inc. — 2025 · $5.8B · Mixed — partial payoff, real shortfalls.
• Novartis AG / Chiron Corporation — 2002 · $5.4B · Mixed — partial payoff, real shortfalls.
• Novartis AG / Molecular Partners AG — 2020 · $780M · Mixed — partial payoff, real shortfalls.
• Novartis AG / Hexal AG and Eon Labs Inc. — 2005 · $8.4B · Mixed — partial payoff, real shortfalls.
• Novartis AG / BeiGene Ltd. — 2021 · $2.2B · Underwhelmed — fell short of the thesis.
• Novartis AG / Sabex Holdings Ltd. — 2004 · $565M · Underwhelmed — fell short of the thesis.
• Novartis AG / Selexys Pharmaceuticals — 2016 · $665M · Underwhelmed — fell short of the thesis.
• Novartis AG / Selexys Pharmaceuticals — 2002 · $665M · Underwhelmed — fell short of the thesis.
• Novartis AG / MorphoSys AG — 2024 · $2.9B · Underwhelmed — fell short of the thesis.
• Novartis AG / Chiron Corporation — 2005 · $5.1B · Underwhelmed — fell short of the thesis.
• Novartis AG / Fougera Pharmaceuticals Inc. — 2012 · $1.5B · Underwhelmed — fell short of the thesis.
• Novartis AG / Chiron Corporation — 2006 · $5.4B · Underwhelmed — fell short of the thesis.
• Novartis AG / Takeda Pharmaceutical Company Ltd. — 2019 · $5.3B · Underwhelmed — fell short of the thesis.
• Novartis AG / Alcon Inc. — 2010 · $51.6B · Underwhelmed — fell short of the thesis.
• Novartis AG / Agenus Inc. — 2017 · $2.6B · Underwhelmed — fell short of the thesis.
• Novartis AG / Ionis Pharmaceuticals, Inc. / Akcea Therapeutics, Inc. — 2016 · $1.4B · Did not work — the deal failed to deliver.
• Novartis AG / CoStim Pharmaceuticals, Inc. — 2014 · Did not work — the deal failed to deliver.
• Novartis AG / Gyroscope Therapeutics — 2021 · $1.5B · Did not work — the deal failed to deliver.
• Novartis AG / Spinifex Pharmaceuticals, Inc. — 2015 · $700M · Did not work — the deal failed to deliver.
• Novartis AG / Speedel Holding AG — 2008 · $880M · Did not work — the deal failed to deliver.
• Novartis AG / Ziarco Group Limited — 2016 · $420M · Did not work — the deal failed to deliver.
• Novartis AG / Unnatural Products, Inc. — 2026 · $1.8B
• Novartis AG / SciNeuro Pharmaceuticals — 2026 · $1.7B
• Novartis AG / Excellergy, Inc. — 2026 · $2.0B
• Novartis AG / Antares Therapeutics, Inc. — 2026 · $1.9B
• Novartis AG / Pikavation Therapeutics, Inc. — 2026 · $3.0B
• Novartis AG / Zonsen PepLib Biotech Inc. — 2026
• Novartis AG / Argo Biopharmaceutical Co., Ltd. — 2025 · $5.3B
• Novartis AG / Relation Therapeutics Limited — 2025 · $1.8B
• Novartis AG / Avidity Biosciences, Inc. — 2025 · $12.0B
• Novartis AG / Arrowhead Pharmaceuticals Inc. — 2025 · $2.2B
• Novartis AG / Kyorin Pharmaceutical Co., Ltd. — 2025 · $833M
• Novartis AG / Tourmaline Bio, Inc. — 2025 · $1.4B
• Novartis AG / Mariana Oncology Inc. — 2024 · $1.8B
• Novartis AG / Voyager Therapeutics Inc. — 2023 · $1.3B
• Novartis AG / Voyager Therapeutics Inc. — 2022 · $1.8B
• Novartis AG / Xiidra (lifitegrast) from Takeda — 2019 · $5.3B
• Novartis AG / IFM Tre, Inc. — 2019 · $1.6B
• Novartis AG / Aduro Biotech, Inc. (STING pathway program) — 2015 · $750M

← Deal Library  ·  Interactive search  ·  How we score deals